CA2274675A1 - Complexe vegf-b/recepteur et utilisations dudit complexe - Google Patents

Complexe vegf-b/recepteur et utilisations dudit complexe Download PDF

Info

Publication number
CA2274675A1
CA2274675A1 CA002274675A CA2274675A CA2274675A1 CA 2274675 A1 CA2274675 A1 CA 2274675A1 CA 002274675 A CA002274675 A CA 002274675A CA 2274675 A CA2274675 A CA 2274675A CA 2274675 A1 CA2274675 A1 CA 2274675A1
Authority
CA
Canada
Prior art keywords
vegf
receptor
binding
flt
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002274675A
Other languages
English (en)
Inventor
Eija Korpelainen
Yuji Gunji
Kari Alitalo
Birgitta Olofsson
Ulf Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Helsinki University Licensing Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2274675A1 publication Critical patent/CA2274675A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne d'une part des complexes de facteurs B de croissance de l'endothélium vasculaire (VEGF-B) et le récepteur de la tyrosine kinase Flt-1; d'autre part, l'utilisation desdits complexes VEGF-B/Flt-1 dans des dosages en vue d'identifier le VEGF-B et les analogues de VEGF-B caractérisés par le fait qu'ils ont sensiblement la même affinité de liaison vis-à-vis d'un récepteur de surface cellulaire tel que le VEGF-B, et/ou qu'ils favorisent une réponse cellulaire induite par VEGF-B ou s'opposent à celle-ci; enfin, l'invention concerne les partenaires de liaison spécifiques desdits complexes de VEGF-B/Flt-1, par exemple, des anticorps.
CA002274675A 1996-12-20 1997-12-19 Complexe vegf-b/recepteur et utilisations dudit complexe Abandoned CA2274675A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3369796P 1996-12-20 1996-12-20
US60/033,697 1996-12-20
PCT/US1997/023533 WO1998028621A1 (fr) 1996-12-20 1997-12-19 Complexe vegf-b/recepteur et utilisations dudit complexe

Publications (1)

Publication Number Publication Date
CA2274675A1 true CA2274675A1 (fr) 1998-07-02

Family

ID=21871932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274675A Abandoned CA2274675A1 (fr) 1996-12-20 1997-12-19 Complexe vegf-b/recepteur et utilisations dudit complexe

Country Status (6)

Country Link
EP (1) EP0960334A1 (fr)
JP (1) JP2000516478A (fr)
AU (1) AU742779B2 (fr)
CA (1) CA2274675A1 (fr)
WO (1) WO1998028621A1 (fr)
ZA (1) ZA9711456B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
WO2021092580A1 (fr) 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Peptides et méthodes de traitement du sepsis, de l'athérosclérose, de la thrombose, de l'accident vasculaire cérébral, de l'attaque cardiaque et de l'inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor

Also Published As

Publication number Publication date
EP0960334A1 (fr) 1999-12-01
AU742779B2 (en) 2002-01-10
ZA9711456B (en) 1998-06-30
JP2000516478A (ja) 2000-12-12
WO1998028621A1 (fr) 1998-07-02
AU5613698A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
Roeckl et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
EP0956339B1 (fr) Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
US6221839B1 (en) FIt4 ligand and methods of use
EP0694042B1 (fr) Inhibiteur du facteur de croissance de cellules endotheliales vasculaires
CA2224093C (fr) Facteur de croissance endotheliale vasculaire 2 humain
US6355440B1 (en) Assays using receptors for fibroblast growth factors
US20050176103A1 (en) Vascular endothelial growth factor 2
US20060025331A1 (en) Vascular endothelial growth factor 2
AU780593B2 (en) Novel neuropilin/growth factor binding and uses thereof
AU742779B2 (en) VEGF-B/receptor complex and uses thereof
Kumar et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates
CA2413012A1 (fr) Facteur de croissance endotheliale vasculaire 2 humain

Legal Events

Date Code Title Description
FZDE Dead